Global Market Study on CAR T-cell Therapy: The Future of Cancer Treatment


Car T Cell Therapy  Market
  • Published On : Nov-2019 |
  • Pages : 150 Pages |
  • Format : Car T Cell Therapy  Market Car T Cell Therapy  Market Car T Cell Therapy  Market Car T Cell Therapy  Market

Cancer Therapy Holds Lucrative Potential for CAR T-Cell Therapy Application

Global CAR T-cell therapy market is projected to witness robust growth during the forecast period (2019-2026). Various innovations under CAR T-cell therapy as well as recent launches of different CAR T-cell therapy drugs in regional markets are further expected to drive the growth of market during the assessment period.

North America would remain the prominent region for CAR T-cell therapy market stakeholders owing to high product availability within the region. CAR T-cell therapy is majorly used in relapsed or refractory B-cell lymphoma and has been recently approved for acute lymphoblastic leukemia (ALL). Currently, CAR T-cell therapy is being evaluated for the treatment of indications such as multiple myeloma which indicates a positive growth outlook for market.

Critical Need for Immunotherapy

With an alarming rate of increase in prevalence of cancers, the need for breakthrough therapeutic solutions such as CAR T-cell therapy continues to be critical. Recent studies suggest that over 1.7 million new cancer patients are recorded in the U.S. alone, and nearly 4.3 million in China. Lymphoma and leukemia are particularly more prevalent. Reports project around 32,110 new cases of myeloma, 82,310 new cases of lymphoma, and 61,780 new cases of leukemia to be registered in the U.S. by 2019 end.

While these numbers seem to be intimidating, they also signal an opportunity for the growth of CAR T-cell therapy market. Chemotherapy and radiation are currently the only therapies available in most parts of the world. However, the introduction of immunotherapies is disrupting the entire perspective of cancer treatment. CAR T-cell therapy is the latest immunotherapy type for cancer treatment, post success of the immune checkpoint inhibitors for cancer treatment.

Eyeing Improved Efficacy of Cancer Treatment

CAR T-cell therapy is developed from the person’s own T-cells i.e. by using person’s own immune cells against cancer cells. This helps in targeting cancer cells more precisely underlining the novel nature of CAR T-cell therapy. CAR T-cell therapy is preferred in patients who have stopped responding to available treatment options. CAR T-cell therapy has also increased the rate of cancer remission.

CAR T-cell therapy is a single infusion therapy and does not require frequent visits to the healthcare settings and improves patient compliance. Two marketed CAR T-cell therapy products are Kymriah (Novartis AG) and Yescarta (Gilead Sciences Inc.). These two products have showcased 83% and 72% rate of putting patient in remission, respectively, in case of B-cell non-Hodgkin lymphoma.

Academic Institutes Emerging as Research Organizations

The field of immuno-oncology is booming with billions of research & development funding for evaluation of new therapies. Growing partnership of academic institutes and private research centers with various pharmaceutical & biopharmaceutical companies is helping in clinical evaluation of various potential cancer therapies and also managing R&D expenditure. Basic research continues to be prominently carried out at academic institutes & private research centers as companies focus on commercializing their products with an eye towards generating profits.

According to the National Science Foundation’s 2015 report, more than 50% of basic research conducted in the U.S. is carried out in academic institutes, whereas over 60% of all applied research and 87% of development of products is carried out in industries. CAR T-cell therapy is also developed by private cancer centers and is being launched in partnership with the biopharmaceutical company.

Novartis developed its CAR T-cell therapy (Kymriah) in collaboration with the University of Pennsylvania (Penn). Kymriah is first FDA approved CAR T-cell therapy for treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (ALL).

Receiving Orphan Drug Designation

Various clinical stage manufacturers received orphan drug designation by the Food and Drug Association (FDA) for their CAR T-cell therapy agent, which is further being evaluated for various cancer treatments.

  • In July 2019 MB-102 (Mustang Bio) a CAR T-cell therapy agent received FDA orphan drug designation for treatment of acute myeloid leukemia. MB-102 is being co-developed by Mustang Bio along with City of Hope National Medical Center
  • In September 2019, CT053 (CARsgen Therapeutics) received orphan drug designation for treatment of multiple myeloma 

Analyst’s Viewpoint

CAR T-cell therapy market growth is majorly driven by the product launches, expansion of manufacturing facilities in different region and extensive number of products in late stage of clinical development. Currently, Novartis AG and Gilead Sciences Inc. are the only players operating in the CAR T-cell therapy market. Key players are prominently focusing on increasing their product availability in different countries and are specifically targeting treatment of Relapsed Large B-cell Lymphoma and ALL. Gradually increasing number of various regional, small & medium manufacturers clinically evaluating CAR T-cell therapy agents expected to crowd the market place over the forecast period.

CAR T-Cell Therapy Market - Scope of the Report

Persistence Market Research (PMR) recently published a market study on the global market for CAR T-cell therapy. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the CAR T-cell therapy market structure. The market study presents exclusive information about how the CAR T-cell therapy market will grow during the forecast period 2019 - 2026.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the CAR T-cell therapy market during the forecast period.

The study is relevant for stakeholders in the CAR T-cell therapy market, including CAR T-cell therapy products manufactures, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the CAR T-cell therapy market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR’s study.

The study also includes statistics as well as facts related to macroeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the CAR T-cell therapy market. Furthermore, small businesses and new entrants in the CAR T-cell therapy market too can make use of the information presented in this study, based on, which they can make appropriate business decisions to gain momentum in the CAR T-cell therapy market.

Key Segments of CAR T-Cell Therapy Market

PMR’s study on the CAR T-cell therapy market offers information divided into four important segments-product, function, application, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Product

Indication

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Lisocabtagene Maraleucel
  • bb2121
  • Relapsed Large B-cell Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Multiple Myeloma  

End-User

Region

  • Hospitals
  • Cancer Treatment Centers
  • North America
  • Europe
  • Japan

Key Questions Answered in PMR’s CAR T-Cell Therapy Market Report

  • Which regions will continue to remain the most profitable regional markets for CAR T-cell therapy market players?
  • Which factors will essentially induce a change in the demand for CAR T-cell therapy in the forecast period?
  • How will changing trends impact the CAR T-cell therapy market?
  • What are key manufacturers’ strategy to enhance their product adoption and improve regional product footprints?
  • Which companies are leading the CAR T-cell therapy market?
  • What are the winning strategies of stakeholders in the CAR T-cell therapy market to upscale their position in this landscape?

CAR T-Cell Therapy Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the CAR T-cell therapy market, and reach conclusions on future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of conclusions.

Secondary resources referred to analysts during the production of the CAR T-cell therapy market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the CAR T-cell therapy market, and makes PMR’s projection on the growth prospects of the CAR T-Cell therapy market more accurate and reliable.

Companies covered in Car T Cell Therapy Market Report

Company Profile

  • Novartis AG
  • Gilead Sciences Inc.
  • Celgene Corporation
  • bluebird bio, Inc.

 

Back To Top